Benzinga

Benzinga

Benzinga

jeudi, août 27

AbbVie Inc

ABBVNYSE
Trade with Public
Trade with Public
$262.90
-2.89-1.09%
À la clôture: Aug 25, 5:00 PM EST
$259.99
-5.80-2.18%
Pré-ouverture: 6:36 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatDividendesComparerOptionsRapport sur les stocks

AbbVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbbVie (ABBV).

Price Target Range — 8 Quarters

Analyst Consensus — 25 Analysts

21Buy
4Hold
Consensus RatingBuy# Analysts25Avg. Consensus PT$263Upside to Avg. PT+1.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 20, 2026Piper SandlerDavid AmsellemPT RaiseOverweight$298→$303
Aug 17, 2026Wells FargoMohit BansalPT RaiseOverweight$295→$300
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303

Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $298 to $303.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.
Benzinga Newsdesk

PRO
Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target

Wolfe Research analyst Alexandria Hammond upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.
Benzinga Newsdesk

PRO
BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247

BNP Paribas analyst Navann Ty maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $260

Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on AbbVie, Raises Price Target to $288

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $261 to $288.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved